1. Five new sustained-release dosage forms of valproic acid (VPA) were developed. 2. The new sustained-release formulations were administered to six healthy subjects for comparison with a standard tablet and an i.v. preparation of the drug. 3. Three of the formulations exhibited a more prolonged and
Comparative pharmacokinetic analysis of a novel sustained release dosage form of valproic acid in dogs
โ Scribed by Meir Bialer; Michael Friedman; Joseph Dubrovsky
- Publisher
- John Wiley and Sons
- Year
- 1984
- Tongue
- English
- Weight
- 385 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
โฆ Synopsis
A new sustained release dosage form of valproic acid (VPA) was developed. The new sustained release dosage form was administered (twice, with and without food) to five dogs in comparison to a standard tablet (Depakine, Labaz) and an i.v. preparation of the drug. Drug level monitoring in the plasma was performed by a GLC assay. Results indicate that the sustained release formulation exhibited a more prolonged and uniform absorption rate, yielded more sustained plasma levels after ingestion, and showed an overall bioavailability of 0.84 (95 per cent C.I. = 0.72, 0.96) relative to an equivalent dose of a conventional tablet.
๐ SIMILAR VOLUMES
A pharmacokinetic analysis of two sustained-release dosage forms of theophylline (Theo-Dur@ and Theotrim@) was carried out following single and multiple dose administrations of the two formulations in five healthy subjects. Despite the prolonged absorption after administration of the two sustained-r